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Abstract
The efficacy of B-cell depletion therapy in rheumatoid arthritis (RA)
has led to a renewed interest in B cells and their products and the
role they play in the pathogenesis of the disease. Agents blocking
tumour necrosis factor (TNF) are also very effective in the treat-
ment of RA. It has long been known that the use of anti-TNF
therapy can be associated with development of anti-nuclear and
anti-double-stranded DNA antibodies and, more rarely, a lupus-like
syndrome. Recently, studies have been published investigating
further possible effects of anti-TNF agents on B cells and whether
these could contribute to their effectiveness in RA.
Both blocking tumour necrosis factor (TNF) and depleting B
cells are effective therapeutic strategies in rheumatoid
arthritis (RA). Recently, some articles have focused on possible
effects of anti-TNF agents on B cells, exploring whether this
could contribute to the efficacy of these agents in the
treatment of RA. In a study published in a recent issue of
Arthritis Research & Therapy, Souto-Carneiro and colleagues
[1] described a decrease in circulating pre-switch
IgD+CD27+ memory B cells in patients with RA when
compared with normal controls. Patients with longer disease
duration had increased frequency of post-switch IgD–CD27+
memory B cells when compared with patients with shorter
disease duration or normal controls. Treatment with infliximab
was associated with an increase in the frequency of total and
pre-switch memory B cells whereas no significant changes
were seen in patients treated with only methotrexate.
All B cells express CD19. Naive B cells exit the bone marrow
at a transitional stage, already expressing both IgM and IgD
but expressing higher levels of CD38 and CD24 than naive
mature B cells and still expressing low levels of CD10 [2].
CD27 is a marker of somatic mutation and therefore of
memory B cells [3]. Memory B cells are frequently subdivided
into pre-switch memory B cells, expressing IgD and IgM, and
post-switch memory B cells, no longer expressing IgD and
expressing IgG or IgA.
A few other studies have looked at circulating B-cell subsets
in RA [2-4]. The results described are not consistent. This
may be due to variability within the different RA cohorts (age,
disease duration, disease activity and treatment with anti-TNF
or other disease-modifying anti-rheumatic drugs) and differ-
ences between control groups. It may also be due to
absence of a true pattern of changes in circulating B-cell
subpopulations in patients with RA. Study of possible effects
of anti-TNF therapy on circulating B-cell subsets has also
shown variable results [1,4-6]. A cross-sectional study found
a decreased frequency of circulating total CD27+ memory B
cells in patients with RA treated with etanercept when
compared with patients treated with methotrexate or when
compared with healthy controls [6]. Both pre- and post-
switch memory B-cell subset proportions were decreased
[6]. Although the results are not comparable, the differences
associated with anti-TNF therapy in this study are in contrast
with the changes described by Souto-Carneiro and colleagues
[1]. Other cross-sectional studies did not find differences
between patients on anti-TNF therapy and patients on other
treatments when the frequency of the same B-cell subsets or
expression on B cells of different chemokine receptors was
compared [4,5].
Anti-TNF agents are thought to act mainly by blocking TNF at
the local site of production – the synovium – with the
consequent blocking of TNF effects on cytokine regulation (in
particular, reducing levels of interleukin-6 [IL-6] and IL-1), cell
recruitment (reduced expression of adhesion molecules and
chemokines, resulting in decreased migration of circulating
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leucocytes into inflamed joints), angiogenesis and tissue des-
truction [7]. However, TNF and a related cytokine, lympho-
toxin alfa (LTα), also play an important role in the develop-
ment and homeostasis of secondary lymphoid organs [8].
Studies in mice suggest that TNF plays a major role in the
formation of Peyer’s patches and the organisation of the
spleen, particularly the compartmentalisation of B and T cells
and the establishment of the marginal zone [8]. In general,
TNF and soluble LTα are thought to have overlapping roles in
this setting, although LTα may play a predominant role in
promoting the formation of tertiary lymphoid tissue at sites of
chronic inflammation [8,9]. Whether differences between the
two main groups of anti-TNF agents, the receptor fusion
protein (etanercept) and the monoclonal anti-TNF antibodies
(infliximab and adalimumab), could have any consequence on
the effect of these agents on B-cell homeostasis or function
is not known. The main clinical differences between these
agents are usually attributed to the fact that the monoclonal
antibodies may be able to lyse cells that express TNF on their
surface. Etanercept, the receptor fusion protein, can bind not
only TNF but also LTα. Nevertheless, both treatment with
infliximab and adalimumab and treatment with etanercept
have been associated with decreased lymphoid follicle
structures in the inflamed synovia [10].
Souto-Carneiro and colleagues [1] suggest that the decrease
in circulating pre-switch memory B cells in RA patients is due
to the accumulation of these cells in the inflamed synovia and
that blocking the effects of TNF decreases trafficking into and
retention of B cells in the synovia, thereby increasing their
proportion in the peripheral blood. However, both pre- and
post-switch memory B cells can be found in the synovia and
no changes were seen in the post-switch subset following
treatment with infliximab. In mice, the absence of TNF affects
the organisation of the spleen marginal zone [9]. In humans,
at least a subset of the circulating pre-switch memory B cells
is thought to be related to the marginal zone in the spleen
[11,12]. An alternative explanation for the changes observed
when patients were treated with infliximab could be an
increased formation or circulation of pre-switch memory B
cells by interfering with follicular dendritic cell function and
germinal centre formation in secondary lymphoid tissues,
including the spleen [12]. Recently, a decrease in follicular
cell networks and germinal centre structures was described
in tonsils of RA patients treated with etanercept [6].
It is still unclear what effects anti-TNF treatment can have on
B cells in RA and whether any effects influence the efficacy of
these agents. In patients with RA, anti-TNF agents sometimes
can induce a sustained response that persists after the drug
is stopped. It will be interesting to investigate whether any
effects that anti-TNF agents can have on B-cell function and
homeostasis could contribute to this sustained response.
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